Search Results 751-760 of 18348 for alopecia

1. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia). Washout from trastuzumab or hormonal therapy is not required. Participants who are currently receiving any other investigational agents. History ...

2. Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma - Mayo Clinic

   Residual Grade ≤ 2 toxicity from chemotherapy (e.g., alopecia, neuropathy) may be allowed. Major surgery within 4 weeks prior to the first IMP ...

3. https://www.mayoclinic.org/chinese_patient_consumer_video.xml

4. A Study Of AL101 In Patients with Adenoid Cystic Carcinoma Bearing Activating Notch Mutations - Mayo Clinic

   0) ≤ Grade 1, except for sensory neuropathy with resolution to ≤ Grade 2 and alopecia. Male and/or Female: Contraceptive use by men or women should be ...

5. A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread - Mayo Clinic

   ... alopecia or peripheral neuropathy. For Part F and H: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed. Exclusion Criteria: Have ...

6. A Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer - Mayo Clinic

   Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, ...

7. When someones weight loss journey hasnt gone as planned

   Simon Laplante, M.D., Metabolic Surgeon, Mayo Clinic: Obesity is a very chronic condition. It's a very complex condition that affects multiple systems in ...

8. Study to Evaluate the Safety, Tolerability and Antitumor Activity of Anti-B7-H3 Car-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma - Mayo Clinic

   The toxicity and side effects caused by previous treatment have not recovered to ≤ grade 1 (per CTCAE 5.0); except for alopecia and other tolerable events ...

9. A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma - Mayo Clinic

   Patients with Grade 2 neuropathy or Grade 2 alopecia are eligible. Active idiopathic thrombocytopenic purpura. Active central nervous system (CNS) ...

10. A Study of SAR442085 in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    ... alopecia). Participant has congestive heart failure (New York Heart Association) Grade ≥ II; cardiac myopathy, active ischemia, or any other uncontrolled ...